List of Excipients in Branded Drug CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Perrigo New York Inc	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE	calcipotriene and betamethasone dipropionate	45802-989	.ALPHA.-TOCOPHEROL, DL-
Perrigo New York Inc	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE	calcipotriene and betamethasone dipropionate	45802-989	BUTYLATED HYDROXYTOLUENE
Perrigo New York Inc	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE	calcipotriene and betamethasone dipropionate	45802-989	MINERAL OIL
Perrigo New York Inc	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE	calcipotriene and betamethasone dipropionate	45802-989	PETROLATUM

Generic Drugs Containing CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	calcipotriene and betamethasone dipropionate	0713-0848	HYDROGENATED CASTOR OIL
Cosette Pharmaceuticals Inc	calcipotriene and betamethasone dipropionate	0713-0848	MINERAL OIL
Cosette Pharmaceuticals Inc	calcipotriene and betamethasone dipropionate	0713-0848	PPG-11 STEARYL ETHER
Sandoz Inc	calcipotriene and betamethasone dipropionate	0781-7165	.ALPHA.-TOCOPHEROL, DL-

What are the Most Frequently-Used Excipients in CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE?

# Of NDCs	Excipient
9	.ALPHA.-TOCOPHEROL, DL-
4	BUTYLATED HYDROXYTOLUENE
1	DIAZOLIDINYL UREA
6	HYDROGENATED CASTOR OIL

Calcipotriene and Betamethasone Dipropionate Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Calcipotriene and betamethasone dipropionate is a fixed-dose topical combination for plaque psoriasis. Its commercial value depends less on the active ingredients, which are established and largely genericized, than on formulation performance: chemical stability, dose uniformity, skin deposition, cosmetic acceptability, packaging, and differentiated delivery.

The strongest opportunities are non-sterile topical products that improve patient adherence through low-residue vehicles, rapid absorption, short application times, easier scalp delivery, and reduced use of propellants or sensitizing excipients. Existing products demonstrate four principal formulation platforms: ointment, topical suspension, aerosol foam, and aqueous or emulsion-based cream.

What products contain calcipotriene and betamethasone dipropionate?

The combination is marketed under several branded and generic formulations in the United States and other major markets.

Product or formulation	Approximate strength	Dosage form	Commercial positioning
Taclonex ointment	Calcipotriene 0.005% and betamethasone dipropionate 0.064%	Ointment	Occlusive, high-emollience vehicle
Taclonex topical suspension	Same	Suspension	Scalp and body application
Enstilar foam	Same	Aerosol foam	Rapid, cosmetically acceptable application
Wynzora cream	Same	Cream	Non-foam, low-residue alternative
Generic products	Same or equivalent strengths	Ointment, suspension, cream	Price-led substitution and formulary access

The FDA approved Taclonex ointment in 2006 and Taclonex topical suspension in 2008. Enstilar foam was approved in 2015, and Wynzora cream was approved in 2020. Product labeling establishes the approved indications, dosage limits, age restrictions, application instructions, and excipient composition for each formulation (U.S. Food and Drug Administration [FDA], 2006, 2008, 2015, 2020).

How does the formulation work?

Calcipotriene is a vitamin D analog that regulates keratinocyte proliferation and differentiation. Betamethasone dipropionate is a potent corticosteroid that reduces inflammation and immune activity. The formulation must deliver both compounds to psoriatic plaques while minimizing systemic exposure and local irritation.

The main technical challenge is compatibility. Calcipotriene is sensitive to acidic conditions and can degrade in the presence of certain excipients, including some fatty acids and acidic preservatives. Betamethasone dipropionate is lipophilic and requires a vehicle that supports solubilization or uniform dispersion. The combination therefore favors controlled-pH, low-water or anhydrous systems, carefully selected surfactants, antioxidants, and packaging that limits light, oxygen, and moisture exposure.

Key formulation constraints

Constraint	Formulation consequence
Calcipotriene chemical instability	Avoid acidic excipients and uncontrolled aqueous environments
Betamethasone dipropionate lipophilicity	Use an oil phase, emollient system, solvent, or dispersed solid phase
Low-dose active ingredients	Tight content-uniformity control is required
Potent corticosteroid	Minimize excess delivery and unintended systemic exposure
Patient reluctance toward greasy products	Favor low-residue creams, foams, gels, or sprays
Scalp and hair application	Reduce tack, occlusion, residue, and rinsing burden
Long-term treatment expectations	Control irritation, odor, staining, and cosmetic defects

What excipients are used in existing formulations?

Existing products use different excipient strategies rather than a single universal vehicle. Their compositions illustrate the main commercial design choices.

Ointment excipients

The ointment platform generally uses mineral oil, paraffin or petrolatum-type hydrocarbons, and a structuring or solubilizing agent. Its advantages are strong emollience, occlusion, and sustained contact with plaques. Its disadvantages are greasiness, transfer to clothing, poor scalp acceptability, and low cosmetic appeal.

Ointment is technically robust because it contains little or no water. The reduced water activity can limit hydrolytic degradation and simplify preservation. The tradeoff is poor patient adherence in large-area disease.

Topical suspension excipients

The suspension platform uses an oil-based vehicle with suspending and wetting agents. Taclonex topical suspension has used mineral oil and nonionic surfactant systems, including polyoxypropylene-based materials, with antioxidant protection reported in FDA labeling.

Suspensions can deliver poorly soluble actives without forcing complete solubilization. The development risks are sedimentation, redispersibility, particle-size control, dose uniformity, and container orientation. Shake instructions increase user burden and can reduce dose reproducibility.

Aerosol foam excipients

Enstilar uses a pressurized foam system with oil-phase excipients, surfactants, fatty alcohol or paraffin-type structural components, antioxidants, and hydrocarbon or ether propellants. The foam spreads rapidly, collapses on the skin, and reduces the perceived greasiness associated with ointments.

Foam is commercially attractive because it improves application speed and body-hair access. It also creates higher manufacturing, filling, container, valve, and transportation complexity. Propellant selection affects spray performance, flammability classification, environmental compliance, foam density, and active deposition.

Cream excipients

Wynzora uses a cream platform designed to combine the delivery characteristics of an oil-containing vehicle with a less greasy sensory profile. Cream systems can incorporate water, humectants, emollients, silicones, surfactants, and rheology modifiers, but the formulation must maintain calcipotriene stability across the product shelf life.

A successful cream requires more than acceptable appearance. Critical parameters include pH, droplet or particle size, viscosity, phase stability, active distribution, preservative performance, and in-use stability. Cream products can expand use beyond patients who reject ointments or aerosols, particularly where a pump or tube provides clean dosing.

Which excipient strategies offer the best commercial opportunity?

The most attractive strategy is a stable, non-greasy, non-propellant formulation that provides the application speed of a foam with the packaging simplicity of a cream.

1. Low-residue cream

A low-residue cream can compete directly with Wynzora and generic ointments. The opportunity is strongest where patients discontinue treatment because of greasiness, staining, or poor absorption.

Useful excipient classes include:

• Lightweight emollients and esters
• Silicone-based slip agents
• Controlled levels of humectants
• Nonionic emulsifiers
• Rheology modifiers that produce rapid rub-in
• Antioxidants compatible with both actives
• Buffered or self-stabilizing systems that avoid acidic degradation

The formulation should not rely on high levels of propylene glycol or alcohol if irritation is a concern. A lower-irritancy profile can support use on sensitive plaques, although clinical performance must be demonstrated rather than inferred from excipient selection.

2. Propellant-free foam or mousse

A propellant-free foam could capture the application advantages of Enstilar while avoiding aerosol shipping, flammability, and certain packaging costs. Candidate systems include mechanically generated foams, airless pump foams, and surfactant-stabilized mousse systems.

The main technical barrier is maintaining dose uniformity. The product must deliver a reproducible mass per actuation, preserve foam structure during use, and distribute both actives evenly after collapse.

3. Scalp-focused vehicle

Scalp psoriasis remains a specific opportunity because ointments and conventional creams perform poorly in hair-bearing areas. Potential formats include:

• Low-viscosity lotion
• Non-greasy suspension
• Metered spray
• Foam with rapid collapse
• Dropper or precision applicator
• Shampoo-compatible leave-on system

A scalp product should prioritize low residue, minimal hair matting, precise dosing, and easy washout. Packaging and applicator design can be as important as the excipient system.

4. Occlusion-enhanced localized product

A high-occlusion product could target thick plaques on elbows, knees, hands, and feet. The commercial opportunity is narrower but may support premium positioning if the formulation reduces application frequency or treatment duration.

Potential approaches include hydrocarbon ointments, anhydrous gels, adhesive films, and patch-like delivery systems. These formats face greater regulatory and usability risk because occlusion can increase corticosteroid penetration and local adverse effects.

How should excipients be selected for stability?

Excipient selection should begin with a compatibility matrix for both active ingredients. The primary development objective is to prevent calcipotriene degradation without reducing betamethasone dipropionate uniformity or skin delivery.

Stability priorities

Development issue	Recommended control
Acid-catalyzed calcipotriene degradation	Avoid acidic excipients; control pH where water is present
Oxidation	Evaluate antioxidants, oxygen exposure, and headspace
Light sensitivity	Use opaque tubes, laminated packaging, or light-protective containers
Water-driven instability	Minimize free water or use a controlled emulsion system
Active adsorption	Screen container-contact materials and surfactants
Phase separation	Establish accelerated and freeze-thaw stability
Sedimentation	Control particle size, viscosity, and suspension structure
Dose variation	Validate mixing, filling, and actuation performance

Anhydrous formulations offer a meaningful stability advantage, but they can be less cosmetically acceptable. Aqueous creams can produce stronger consumer acceptance but require more extensive testing for pH drift, preservative efficacy, microbial quality, and active degradation.

What formulation patents protect calcipotriene and betamethasone products?

The principal intellectual-property value is concentrated in formulation, delivery, and manufacturing claims rather than composition-of-matter claims for the active ingredients.

Potentially protectable subject matter includes:

• Specific ratios of calcipotriene to betamethasone dipropionate
• Anhydrous or substantially anhydrous vehicles
• Particle-size ranges
• Foam density and collapse characteristics
• Propellant combinations
• Specific emulsifier and emollient systems
• pH-controlled creams
• Packaging and dispensing systems
• Improved chemical stability
• Reduced degradation products
• Enhanced skin penetration or deposition
• Treatment regimens and reduced application frequency

U.S. Orange Book-listed patents for approved combination products may cover formulations, dosage forms, or methods of use. Patent scope and listing status vary by product and can change through patent expiration, delisting, litigation, or regulatory action. The FDA Orange Book remains the controlling source for current listed patents and regulatory exclusivity information (FDA, 2024).

A new entrant should avoid relying on a formulation that is merely cosmetically different. A commercially meaningful patent position generally requires a measurable technical result, such as improved stability, reduced degradation, superior dose uniformity, increased skin deposition, or an improved clinical endpoint.

When does calcipotriene and betamethasone dipropionate lose exclusivity?

The active ingredients have long-established composition-of-matter histories. Commercial exclusivity therefore depends on product-specific patents, regulatory exclusivity, and market acceptance of generic or follow-on topical products.

Product	FDA approval milestone	Primary exclusivity issue
Taclonex ointment	2006	Legacy formulation patents and generic competition
Taclonex suspension	2008	Formulation and method-of-use protection
Enstilar foam	2015	Foam formulation, aerosol system, and listed patents
Wynzora cream	2020	Cream formulation and delivery-related protection

Small-molecule topical products can face generic competition through abbreviated new drug applications. A generic applicant may submit a Paragraph IV certification asserting that listed patents are invalid, unenforceable, or will not be infringed. The reference-product sponsor may respond with patent litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework if the statutory conditions are met.

The practical loss of exclusivity can occur before all patents expire if a generic entrant obtains a favorable litigation outcome, launches at risk, or reaches a settlement. Conversely, a technically difficult topical product may retain commercial differentiation after formal patent expiry because bioequivalence and product sameness are harder to establish than for many oral tablets.

What is the FDA regulatory status of the combination?

Calcipotriene and betamethasone dipropionate products are regulated as prescription topical drugs in the United States. The FDA-approved products differ in dosage form, labeling, age indications, application sites, and duration limits.

Regulatory risk is highest when a new excipient system changes the product's microstructure or delivery profile. A cream with a different vehicle may require comparative clinical data, pharmacodynamic evidence, or a more extensive development program than a conventional generic ointment.

Regulatory pathways

A sponsor may pursue:

1. An ANDA for a product that meets the reference product's pharmaceutical equivalence and bioequivalence requirements.
2. A 505(b)(2) application for a materially different formulation, delivery system, or clinical use.
3. A supplemental pathway for a line extension of an existing product.
4. A combination or device-led strategy where the dispenser materially contributes to performance.

For complex topical products, the critical regulatory package may include in vitro release testing, in vitro permeation testing, comparative product characterization, dermatopharmacokinetic data, irritation studies, and clinical efficacy testing.

How strong is the patent estate for a new excipient platform?

Patent strength depends on claim breadth, technical evidence, freedom to operate, and the ability to demonstrate that the formulation performs differently from prior art.

Patent factor	Strong position	Weak position
Claim scope	Covers composition, process, and performance	Covers only a narrow excipient substitution
Data support	Stability and delivery data across multiple embodiments	One formulation example
Prior art distance	Clear difference from ointment, suspension, foam, and cream art	Routine optimization of known excipients
Commercial relevance	Product improves adherence or dosing	No measurable user or clinical benefit
FTO profile	Limited overlap with listed products	Direct overlap with protected foam or cream systems
Regulatory support	Performance data align with approval pathway	Claims depend on unvalidated superiority

A platform patent should cover the formulation architecture, not only a single named excipient. Claims directed to a defined stability profile, particle-size distribution, or delivery performance can provide stronger commercial protection when supported by comparative data.

Which companies compete in this market?

Competition includes originator companies, specialty dermatology companies, generic manufacturers, and developers of alternative topical corticosteroid or vitamin D analog products.

Key commercial participants include:

• LEO Pharma, associated with Taclonex and Enstilar in major markets
• MC2 Therapeutics, associated with Wynzora
• Generic dermatology manufacturers selling calcipotriene and betamethasone products
• Contract development and manufacturing organizations with topical semisolid and aerosol capabilities
• Companies developing nonsteroidal psoriasis therapies that compete for the same treatment segment

The competitive advantage of a new product will depend on net price, payer coverage, patient preference, application convenience, and prescriber familiarity. A formulation that carries a premium must produce a clear benefit in adherence, tolerability, or treatment persistence.

What commercial opportunities exist by dosage form?

Premium cream

A premium cream has the broadest addressable market. It can target patients who reject greasy ointments and prescribers who want a familiar tube or pump format. The main risks are patent overlap with existing cream products and the need to prove equivalent or superior delivery.

Generic ointment

Generic ointment is the lowest-risk manufacturing opportunity but also the most price-sensitive. Scale, procurement, and payer contracts will determine profitability. Excipient differentiation is limited unless the product improves spreadability, stability, or preservative tolerance.

Scalp foam or spray

Scalp delivery has stronger differentiation potential. A low-residue product with a precision applicator can command a premium if it improves use in hair-bearing areas. Device patents and combination-product requirements may create additional barriers.

Propellant-free foam

This is a potentially valuable platform for reformulation. It can reduce aerosol-related logistics and appeal to patients seeking a less greasy product. Manufacturing reproducibility and actuation performance are the central risks.

Combination moisturizing system

A product that combines active treatment with a moisturizer may improve adherence and reduce the need for separate emollient use. The claims must avoid implying unapproved disease modification unless supported by clinical data. The excipient system must also preserve active stability over the full shelf life.

What manufacturing and IP barriers affect market entry?

Manufacturing barriers are moderate for ointments and creams but higher for foams and finely dispersed suspensions.

Manufacturing considerations

• High-shear mixing may affect active dispersion and particle size.
• Heat exposure can accelerate degradation during emulsification.
• Homogeneity must be maintained at very low active concentrations.
• Aerosol filling requires specialized equipment and validated valves.
• Tube, pump, and actuator materials can affect sorption and dose delivery.
• Scale-up can change viscosity, droplet size, foam density, and release behavior.
• Cleaning validation is important where potent corticosteroids are manufactured in multiproduct facilities.

The most defensible commercial strategy is often a formulation-device combination. A well-designed dispenser can improve dose consistency and create a separate patent layer, although it may increase regulatory complexity.

What generic launch risks exist?

Generic launch risk is highest for simple ointments and lower for technically complex foams or creams, but the distinction is product-specific.

Risk	Ointment	Suspension	Foam	Cream
Formulation complexity	Low	Moderate	High	Moderate to high
Bioequivalence difficulty	Moderate	Moderate	High	High
Manufacturing investment	Low	Moderate	High	Moderate
Price erosion	High	High	Moderate	Moderate
Patient switching resistance	Low	Moderate	Higher	Moderate
Device or container dependency	Low	Low	High	Moderate

A generic applicant may challenge listed patents through Paragraph IV certification. The reference sponsor may pursue litigation involving formulation claims, method-of-use claims, or infringement based on product composition. Settlement agreements can define launch dates, licensed entry rights, or restrictions on the generic product. Their business impact depends on the remaining patent term, authorized-generic strategy, and payer substitution rules.

Is biosimilar risk relevant?

Biosimilar risk is not relevant to calcipotriene and betamethasone dipropionate because the product is a small-molecule drug, not a biologic. The relevant competitive risks are ANDA-based generic entry, 505(b)(2) reformulations, authorized generics, and branded topical alternatives.

Nonsteroidal competitors, including topical PDE-4 inhibitors, topical JAK inhibitors, and other psoriasis therapies, may reduce demand without directly challenging the combination's patents. Their effect is greatest in mild-to-moderate disease and maintenance-treatment segments.

How should a company prioritize an excipient development program?

A commercially focused program should rank formulations by stability, patient usability, regulatory pathway, and patent differentiation.

Priority	Product concept	Commercial rationale
1	Non-greasy propellant-free cream or mousse	Broadest patient appeal and differentiated delivery
2	Scalp-specific low-residue foam or spray	Clear unmet usability need
3	Stable low-irritancy cream	Potential 505(b)(2) or premium generic position
4	Improved suspension	Moderate differentiation, but shake and sedimentation issues remain
5	Conventional ointment	Lowest technical risk but highest price pressure

The preferred excipient strategy is a low-water or tightly controlled emulsion system using nonionic, low-irritancy excipients; light- and oxygen-protective packaging; and a dispenser that delivers consistent dosing without excessive product waste.

Key Takeaways

• Calcipotriene and betamethasone dipropionate is an established topical combination whose commercial value now depends on formulation and delivery.
• Ointments are technically robust but have poor cosmetic acceptability.
• Suspensions address scalp and body use but create dose-uniformity and redispersion challenges.
• Aerosol foams offer strong patient appeal but require specialized manufacturing, packaging, and regulatory controls.
• Creams have the broadest commercial opportunity, especially when they reduce greasiness and application time.
• Calcipotriene stability makes pH, water activity, antioxidant selection, and packaging central development variables.
• Formulation, device, manufacturing, and method-of-use patents are more important than active-ingredient patents.
• Generic competition is the primary exclusivity threat; biosimilar competition does not apply.
• A propellant-free, low-residue cream or mousse is the most attractive platform for differentiated commercial entry.
• A scalp-specific product may command premium pricing if it delivers precise dosing without hair matting or difficult washout.

Frequently Asked Questions

Can propylene glycol be used in calcipotriene and betamethasone formulations?

It can be evaluated as a solvent or humectant, but its use requires compatibility, irritation, stability, and permeation testing. Its concentration should be optimized against calcipotriene stability and patient tolerability.

What packaging is best for this combination?

Opaque laminated tubes, airless pumps, and other low-oxygen containers are strong candidates. The final choice depends on viscosity, light sensitivity, dose accuracy, active-container compatibility, and in-use stability.

Can a new cream obtain market exclusivity after older products lose patent protection?

Yes. A new cream may obtain patent protection for a novel composition, delivery system, manufacturing process, or method of use. Regulatory exclusivity depends on the approval pathway and product-specific FDA designation.

Does changing the excipient create a new drug product?

Not automatically. A minor excipient change may support a generic or supplemental pathway, while a materially different vehicle or delivery profile may require a 505(b)(2) application and additional clinical or comparative-performance data.

Which active ingredient creates the greater formulation challenge?

Calcipotriene generally creates the greater chemical-stability challenge. Betamethasone dipropionate creates a greater solubility and distribution challenge because of its lipophilic properties. The vehicle must address both problems simultaneously.

References

1. U.S. Food and Drug Administration. (2006). Taclonex ointment prescribing information.
2. U.S. Food and Drug Administration. (2008). Taclonex topical suspension prescribing information.
3. U.S. Food and Drug Administration. (2015). Enstilar foam prescribing information.
4. U.S. Food and Drug Administration. (2020). Wynzora cream prescribing information.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355.
7. U.S. Food and Drug Administration. (2023). Draft guidance for industry: ANDAs for certain highly purified synthetic and semisynthetic drug substances.